By Chelsea Naso ( March 8, 2019, 6:14 PM EST) -- A Versum Materials investor blasted the adoption of an "overly restrictive" poison pill after Merck KGaA's $6 billion challenge to the company's planned Entegris merger, contending in a Delaware Chancery suit Friday that it shows board members are acting in their own best interest....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.